Molecular analysis of p21 and p27 genes in human pituitary adenomas

British Journal of Cancer

Volumn 76, Issue 9, 1997, Pages 1119-1123

  Ikeda, H ^a   Yoshimoto, T ^a   Shida, N ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cyclin dependent kinase inhibitor; P21; P27; Polymerase chain reaction single strand conformational polymorphism; Reverse transcription polymerase chain reaction

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN P21;

ADULT; AGED; ARTICLE; CANCER GENETICS; CARCINOGENESIS; CELL CYCLE; FEMALE; GENE MUTATION; GENE REPRESSION; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REGULATOR GENE; RETINOBLASTOMA; SINGLE STRAND CONFORMATION POLYMORPHISM; TRANSCRIPTION REGULATION; TRANSLATION REGULATION;

EID: 0030758940     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.521     Document Type: Article

References (23)

1. Bullrich F, MacLachlan TK, Sang N, Druck T, Veronese ML, Allen SL, Chiorazzi N, Koff A, Heubner H, Croce CM and Giordano A (1995) Chromosomal mapping of members of the cdc2 family of protein kinases, cdk3, cdk6, PISSLRE, and PITALRE, and a cdk inhibitor, p27, to regions involved in human cancer. Cancer Res 55: 1194-1205
2. Cryns VL, Alexander JM, Klibanski A and Arnold A (1993) The retinoblastoma gene in human pituitary tumors. J Clin Endocrinol Metab 77: 644-646
3. Deng C, Zhang P, Harper JW,. Ellede SJ and Leder P (1995) Mice lacking p21 undergo normal development, but are defective in GI checkpoint control. Cell 82: 675-684
4. Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, Polyak K, Tsai LH, Broudy V, Perlmutter RM, Kaushanaky K and Roberts JM (1996) A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterity in p27-deficient mice. Cell 85: 733-744
5. Hengst L and Reed SL (1996) Translational control of p27 accumulation during the cell cycle. Science 271: 1861-1864
6. Hu N, Gustmann A, Herbert DC, Bradley A, Lee WH and Lee EY (1994) Heterozygous Rb-1/+mice are predisposed to tumors of the pituitary gland with a nearly complete penetrance. Oncogene 9: 1021-1027
7. Ikeda H and Yoshimoto T (1991) The developmental changes in proliferative activity of cells of the murine Rathke's pouch. Cell Tissue Res 263: 41-47
8. Ikeda H, Suzuki J, Sasano N and Niizuma H (1988) The development and morphogenesis of the human pituitary gland. Anat Embryol 178: 327-336
9. Ikeda H, Beauchamp RL, Yoshimoto T and Yandell DW (1995) Detection of heterozygous mutation in the retinoblastoma gene in a human pituitary adenoma using PCR-SSCP analysis and direct sequencing. Endocr Pathol 6: 189-196
10. Jacks T, Frazeli A, Schmitt EM, Bronson RT, Goodell MA and Weinberg RA (1992) Effect of an Rb mutation in the mouse. Nature 359: 295-300
11. Kato J, Matsuoka M, Polyak K, Massague J and Sherr CJ (1994) Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27) of cyclin-dependent kinase 4 activation. Cell 79: 487-496
12. Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffman EC, Ono M, Khanam D, Hayday AC, Frohman LA and Koff A (1996) Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27. Cell 85: 721-732
13. Koopmann J, Maintz D, Schild S, Schramm J, Louis DN, Wiestler OD and Von Deimling A (1995) Multiple polymorphism, but no mutations, in the WAF1/CIPI gene in human brain tumors. Br J Cancer 72: 1230-1233
14. MacLachlan TK, Sang N and Giordano A (1995) Cyclin, cyclin-dependent kinases and cdk inhibitors: implication in cell cycle control and cancer. Critical Reviews in Eukaryotic Gene Expression 5: 127-156
15. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY and Nakayama K (1996) Mice lacking p27 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85: 707-720
16. Pietenpol JA, Bohlander SK, Sato Y, Papadopoulos N, Liu B, Friedman C, Trask BJ, Roberts JM, Kinzler KW, Rowley JD and Vogelstein B (1995) Assignment of the human p27 gene to 12p13 and its analysis in leukemias. Cancer Res 55: 1206-1210
17. Pines J (1995) Cyclins, CDKs and cancer. Semin Cancer Biol 6: 63-72
18. Ponce-Castaneda MV, Lee MH, Latres E, Polyak K, Lacombe L, Montgomery K, Mathew S, Krauter K, Sheinfeld J, Massague J and Cordon-Cardo C (1995) p27: chromosomal mapping to 12p12-12p13.1 and absence of mutation in human tumors. Cancer Res 55: 1211-1214
19. Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P and Massague J (1994) Cloning of p27, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78: 59-66
20. Shiohara M, Ei-Deiry WS, Wada M, Nakamaki T, Takeuchi S, Yang R, Chen DL, Vogelstein B and Koeffler HP (1994) Absence of WAF1 mutations in a variety of human malignancies. Blood 84: 3781-3784
21. Toyoshima H and Hunter T (1994) p27, a novel inhibitor of G1 cyclin-cdk protein kinase activity, is related to p21. Cell 78: 67-74
22. Ueki K, Ono Y, Henson JW, Efird JT, Von Deimling A and Louis DN (1996) CDKN2/p16 or RB alteration occur in the majority of glioblastoma and are inversely correlated. Cancer Res 56: 150-153
23. Woloschak M, Yu A, Xiao J and Post KD (1996) Frequent loss of the p16 gene product in human pituitary tumors. Cancer Res 56: 2493-2496